As per MRFR analysis, the UK Biosimilar Contract Manufacturing Market Size was estimated at 325.06 (USD Million) in 2023. The UK Biosimilar Contract Manufacturing Market Industry is expected to grow from 386.5(USD Million) in 2024 to 2,063.7 (USD Million) by 2035. The UK Biosimilar Contract Manufacturing Market CAGR (growth rate) is expected to be around 16.449% during the forecast period (2025 - 2035).
The UK Biosimilar Contract Manufacturing Market is experiencing substantial growth, which is being driven by critical market drivers, including the increasing prevalence of chronic diseases and the rising cost of healthcare. The UK government has demonstrated a dedication to the integration of biosimilars into the healthcare system through its initiatives to encourage their use in order to decrease expenditures on biologics.
This regulatory support is fostering a favorable environment for contract manufacturers, facilitating their investment in biosimilar production capabilities. Moreover, the region's production capacity for biosimilars is being increased as a result of the continuous improvements in biomanufacturing technologies, which are resulting in increased efficiency.
Opportunities for exploration in the UK market include the potential for collaborations between biotech firms and contract manufacturers, which would enable the firms to capitalise on each other's strengths to expedite the development and production of biosimilars. As a result of the prospective entry of new players into the biosimilar space, existing manufacturers are being compelled to innovate and improve their service offerings, thereby increasing their competitiveness.
In recent years, there has been a discernible trend towards a higher acceptability rate of biosimilars among healthcare professionals and patients. This transition is sustained by the initiatives of numerous health organisations and campaigns in the United Kingdom that are designed to inform stakeholders about the safety and efficacy of biosimilars. Furthermore, the increasing demand for advanced manufacturing solutions is being driven by the increasing prominence of personalized medicine, which is further solidifying the position of biosimilars in the UK healthcare market. The future of the UK biosimilar contract manufacturing market is promising as companies align with evolving regulatory frameworks and industry standards.
Source: Primary Research, Secondary Research, MRFR Database, and Analyst Review
The growing demand for cost-efficient alternatives to expensive biologics is a significant driver for the UK Biosimilar Contract Manufacturing Market Industry. With the National Health Service (NHS) striving to reduce drug costs amid rising healthcare expenditures, biosimilars present a viable solution, as they are generally 20-30% cheaper than their originator biologics.
According to the NHS Long Term Plan, biosimilars could save the healthcare system an estimated 200 million GBP annually by 2025. The influx of manufacturers such as Sandoz and Biocon into the UK market contributes to the availability and variety of biosimilars, facilitating better access for patients and consequently pushing market growth in this sector.
The regulatory environment in the UK is increasingly favorable for the development and approval of biosimilars, driving growth in the UK Biosimilar Contract Manufacturing Market Industry. The Medicines and Healthcare products Regulatory Agency (MHRA) has implemented specific guidelines to streamline the approval process for biosimilars.
This supports quicker market entry for new biosimilars, enhancing competition and accessibility. The European Medicines Agency (EMA) has also endorsed a clear pathway for biosimilar approval, which has influenced the UK as it follows similar practices post-Brexit. Consequently, with over 15 biosimilar products currently approved in the UK, this robust regulatory support encourages investment and innovation in biosimilar manufacturing.
The increasing prevalence of chronic diseases, such as diabetes and cancer, directly fuels the demand for biosimilars in the UK Biosimilar Contract Manufacturing Market Industry. Recent reports indicate that the number of people living with diabetes in the UK has surged to 4.9 million, with projections estimating this number will hit 5.5 million by 2030.
This growing patient population necessitates affordable treatment options like biosimilars for biologic medications. Companies like Amgen and Mylan are focusing resources on developing biosimilars targeting chronic disease treatment, thereby addressing patient needs and expanding market penetration.
Technological advancements in biomanufacturing processes significantly bolster the growth of the UK Biosimilar Contract Manufacturing Market Industry. Innovations such as single-use bioreactors and process intensification enable manufacturers to achieve higher production efficiency while reducing costs.
For instance, recent data suggests that companies adopting these modern technologies can decrease their production costs by up to 30%. As manufacturers like Lonza and WuXi AppTec adopt these cutting-edge processes, the overall viability and attractiveness of entering the biosimilar market increase, which catalyzes further growth in the UK sector.
The UK Biosimilar Contract Manufacturing Market primarily centers around diverse products that play a vital role in the pharmaceutical sector. Within this market, the product segment encompasses crucial categories such as Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins, each catering to distinct therapeutic needs and exhibiting unique characteristics.
Recombinant Non-glycosylated Proteins are essential in the production of various biotherapeutics, facilitating treatment for conditions such as hormonal deficiencies and certain types of cancer.
Their simple structure not only streamlines the manufacturing process but also contributes to their cost-effectiveness, making them appealing for companies looking to reduce production expenses while maintaining efficacy.
In contrast, Recombinant Glycosylated Proteins are indispensable for developing more complex biologic drugs, including enzymes and antibodies, which require precise glycosylation for optimal functionality and therapeutic effects. This sub-segment demonstrates significant advancements, particularly in personalized medicine, where the proper glycosylation can enhance drug efficacy.
The demand for such products is further bolstered by the increasing prevalence of chronic diseases within the UK, prompting a greater push for biosimilar options and biologics that can serve as alternatives to expensive monoclonal antibodies. The UK government has been supportive of initiatives aimed at boosting the biosimilar market, recognizing its potential to enhance access to affordable treatments while also driving innovation in the life sciences industry.
With the ongoing trend towards personalized medicine and greater focus on biopharmaceutical manufacturing, the UK Biosimilar Contract Manufacturing Market is poised to grow, driven by the need for high-quality, efficient production of both Recombinant Non-glycosylated and Glycosylated Proteins. This growth is fueled by the advantages these products provide in terms of treatment accessibility, cost-reduction in healthcare, and improved patient outcomes, ultimately positioning the UK as a key player in the global biosimilars space.
Source: Primary Research, Secondary Research, MRFR Database, and Analyst Review
The Production Technology segment of the UK Biosimilar Contract Manufacturing Market has garnered significant attention due to its pivotal role in the development and production of biosimilars. This segment predominantly consists of two main categories Mammalian and Non-Mammalian production technologies.
Mammalian systems are often favored in the production of complex biologics due to their ability to perform post-translational modifications, which are critical for the functionality of many therapeutic proteins.
The UK government's initiatives to support biopharmaceutical innovation have reinforced the importance of robust mammalian platforms, thereby enhancing the competitiveness of local manufacturers in the biosimilar space.
Conversely, Non-Mammalian technologies, which include microbial systems, are gaining traction for their cost-effectiveness and rapid production capabilities. These systems are especially suitable for simpler proteins and can significantly reduce time-to-market, presenting a strategic advantage in a fast-evolving market.
As the UK Biosimilar Contract Manufacturing Market continues to expand, the adoption of advanced production technologies will likely drive efficiency and scalability, responding to the growing demand for affordable biological therapies in the healthcare sector. The emphasis on innovation within these production methodologies reflects the ongoing efforts by industry players to meet regulatory standards and respond to patient needs, ensuring that the UK remains a key player in the global biosimilars landscape.
The Application segment of the UK Biosimilar Contract Manufacturing Market plays a crucial role in delivering affordable therapeutic solutions across various medical conditions. The Oncology section remains a focal point, driven by the rising prevalence of cancer, necessitating effective biosimilar treatments to improve patient outcomes and reduce healthcare costs.
Blood Disorders are also gaining importance due to the growing patient population requiring advanced therapies, promoting the need for sustainable manufacturing solutions. Additionally, Growth Hormonal Deficiency treatment options are seeing increased demand as awareness of hormonal imbalances rises among the population.
Chronic and Autoimmune Disorders, including Rheumatoid Arthritis, contribute significantly to the market, influenced by the aging population and advancements in biosimilar technology. The UK government’s focus on enhancing healthcare access supports the growth of these application areas, fostering innovations that enable cost-effective treatment pathways. Overall, the insights from the Application segment indicate a diverse landscape with substantial growth opportunities across multiple therapeutic categories, positioning the UK as a significant player in the global biosimilar market.
The UK Biosimilar Contract Manufacturing Market is characterized by a complex interplay of factors driving growth and competition. With an increasing shift towards the use of biosimilars as a cost-effective alternative to originator biologics, the market has seen a heightened interest from both established players and new entrants looking to capitalize on this trend.
The competitive landscape is marked by companies offering specialized manufacturing capabilities, advanced technologies, and a focus on regulatory compliance to meet the stringent guidelines set forth by health authorities. The demand for biosimilars within the UK has been influenced by the rising pressures to reduce healthcare costs while ensuring patient access to biologic therapies, thus presenting opportunities for growth and differentiation among manufacturers.
Sandoz has established a strong presence in the UK Biosimilar Contract Manufacturing Market, leveraging its expertise in biologics and a robust portfolio of biosimilar products. Its strengths lie in its advanced manufacturing facilities, which are compliant with international standards, enabling the company to produce high-quality biosimilars.
Sandoz has positioned itself as a leader through continuous innovation and by fostering partnerships that enhance its development capabilities. The company's focus on sustainability and efficiency in manufacturing processes further contributes to its competitive edge. Additionally, Sandoz has successfully built a solid reputation within the healthcare community in the UK, attributed to its commitment to patient-centric approaches and collaboration with healthcare providers to ensure broader access to affordable therapies.
Novartis plays a pivotal role in the UK Biosimilar Contract Manufacturing Market, primarily driven by its comprehensive portfolio of biosimilars that encompasses a range of therapeutic areas. The company is known for its strong research and development capabilities, which allow it to produce high-quality biosimilar products tailored to specific market needs.
Novartis has gained a significant foothold in the UK through strategic mergers and acquisitions that have bolstered its market presence, allowing it to enhance its manufacturing capabilities and distribution networks. The strengths of Novartis lie in its innovative approach, combined with a dedication to maintaining regulatory compliance and quality assurance throughout its manufacturing processes. The company's various key products and services reflect its commitment to addressing unmet medical needs while ensuring that it remains a competitive force in the rapidly evolving landscape of the UK biosimilar market.
Recent developments in the UK Biosimilar Contract Manufacturing Market have been noteworthy, particularly as companies like Sandoz and Novartis continue to expand their roles in biosimilars. AstraZeneca has been advancing its partnership strategies, particularly in the context of its oncology biosimilars.
The market has seen significant growth, with the valuation of companies such as Merck KGaA and Teva Pharmaceuticals steadily rising, influenced by the increasing demand for cost-effective biologics. This growth trajectory is impacting the overall market dynamics, compelling organizations to enhance their manufacturing capabilities.
In terms of mergers and acquisitions, notable activity includes Pfizer's acquisition of a biologics manufacturing facility in the UK reported in March 2023, which is expected to bolster their production capacity of biosimilars. Also, in August 2022, Amgen announced a collaboration with Fujifilm Diosynth Biotechnologies to optimize the production processes for biosimilars, further emphasizing the collaborative efforts within the industry. Overall, these developments signify a robust and evolving landscape in the UK Biosimilar Contract Manufacturing Market, reflecting the increasing emphasis on biopharmaceutical innovation and efficiency.
| Report Attribute/Metric Source: | Details |
| MARKET SIZE 2018 | 325.06(USD Million) |
| MARKET SIZE 2024 | 386.5(USD Million) |
| MARKET SIZE 2035 | 2063.7(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 16.449% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| MARKET FORECAST PERIOD | 2025 - 2035 |
| HISTORICAL DATA | 2019 - 2024 |
| MARKET FORECAST UNITS | USD Million |
| KEY COMPANIES PROFILED | Sandoz, Novartis, AstraZeneca, Cipla, Merck KGaA, Teva Pharmaceuticals, Mylan, Amgen, Samsung BioLogics, Lonza, AbbVie, Fujifilm Diosynth Biotechnologies, Pfizer, Boehringer Ingelheim |
| SEGMENTS COVERED | Product, Production Technology, Application |
| KEY MARKET OPPORTUNITIES | Increasing demand for cost-effective therapies, Expanding portfolio of biosimilars, Technological advancements in manufacturing, Strategic partnerships with biopharma firms, Growing regulatory support for biosimilars |
| KEY MARKET DYNAMICS | Regulatory approvals, Cost competitiveness, Increasing biosimilar adoption, Advanced manufacturing technologies, Growing chronic disease prevalence |
| COUNTRIES COVERED | UK |
Frequently Asked Questions (FAQ) :
The UK Biosimilar Contract Manufacturing Market is expected to be valued at 386.5 million USD in 2024.
By 2035, the market is projected to reach approximately 2063.7 million USD.
The market is expected to grow at a CAGR of 16.449% from 2025 to 2035.
The Recombinant Non-glycosylated Proteins segment is projected to grow from 230.0 million USD in 2024 to 1230.5 million USD in 2035.
The Recombinant Glycosylated Proteins segment is forecasted to be valued at 833.2 million USD by 2035.
Major players in the market include Sandoz, Novartis, AstraZeneca, and Merck KGaA among others.
Key growth drivers include rising demand for affordable biologics and advancements in biomanufacturing technologies.
Challenges include regulatory hurdles and competition from established biologics.
Opportunities lie in increasing collaboration between biotech firms and contract manufacturers.
The market has seen significant growth due to rising healthcare costs and the increasing adoption of biosimilars.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Analyst Explore the profile of garvit vyas, one of our esteemed authors at market research future, and access their expert research contributions in the field of market research and industry analysis
Get in Touch
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
